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A B S T R A C T
Background: A key component of recent English cancer policy is the monitoring of trends in early diagnosis of
cancer. Early diagnosis can be deﬁned by the disease stage at diagnosis or by other indicators derived from
electronic health records. We evaluate the association between diﬀerent early diagnosis indicators and survival,
and discuss the implementation of the indicators in surveillance of early diagnosis.
Methods: We searched the PubMed database and grey literature to identify early diagnosis indicators and
evaluate their association with survival. We analysed cancer registrations for 355,502 cancer patients diagnosed
in England during the period 2009–2013, and quantiﬁed the association between each early diagnosis indicator
and 30-day mortality and ﬁve-year net survival.
Results: Each incremental diﬀerence in stage (I–IV) predicts lower 5-year survival, so prognostic information is
lost in comparisons which use binary stage indicators. Patients without a recorded stage have high risk of death
shortly following diagnosis and lower 5-year survival. Emergency presentation is independently associated with
lower ﬁve-year survival. Shorter intervals between ﬁrst symptoms and diagnosis are not consistently associated
with improved survival, potentially due to confounding from tumour characteristics.
Interpretation: Contrary to current practice, we recommend that all the stage information should be used in
surveillance. Patients missing stage should also be included to minimise bias. Combined data on stage and
emergency presentation could be used to create summary prognostic measures. More work is needed to create
statistics based on the diagnostic interval that will be useful for surveillance.
1. Introduction
Increasing early-stage diagnosis is a common component of regional
and national strategies to reduce the burden of cancer [1–5]. ‘Early
diagnosis’ is often used as a shorthand for ‘early-stage diagnosis’, which
has historically been the outcome in early diagnosis studies. However,
alternative indicators based on electronic health records are increas-
ingly being used in early diagnosis studies. Some of these indicators
relate to the promptness of diagnosis following clinical presentation, or
the health services patients accessed ﬁrst [6].
In England, cancer surveillance statistics are published on Public
Health England’s ‘CancerData’ dashboard for each of the 209 local
healthcare commissioning bodies (Clinical Commissioning Groups –
CCGs) [7]. These include the percentage of patients diagnosed with
localised tumours (TNM Stage I/II), the percentage diagnosed following
emergency admission or referral, and statistics on adherence to targets
for patient waiting times.
Surveillance in England was only initiated in 2016, and optimal
implementation of the diﬀerent possible indicators in surveillance has
not been extensively researched. Information on the association be-
tween each indicator and short-term mortality and survival will help
analysts interpret the indicators, and identify those which are timely
measures of progress in raising survival from cancer.
In this study, we report a systematic literature review and data
analysis. Our aim is to identify early diagnosis indicators and evaluate
the association between each indicator and short-term mortality and
survival. We then discuss the implications of our ﬁndings for surveil-
lance.
2. Methods
We conducted a systematic literature search to identify indicators of
early cancer diagnosis in population-based data sources and evaluate
their association with short-term mortality and survival. The associa-
tion between each indicator and (i) risk of death within 30 days fol-
lowing diagnosis (“30-day mortality”) (ii) net survival at one and ﬁve
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years was then analysed for patients diagnosed in 2009–2013 in
England with either colorectal cancer, non-small cell lung cancer
(NSCLC) or ovarian cancer, malignancies frequently diagnosed at ad-
vanced stage [8].
2.1. Literature review
2.1.1. PubMed search
Journal articles published between August 2007 and August 2017
were examined [9]. Articles that contained each of three keyword
elements (cancer, early diagnosis, population-based) in the title or the
abstract were retained (Appendix A in Supplementary data).
2.1.2. Google.com search
Google was searched using the same keywords on 25 August 2017.
The ﬁrst 20 hyperlinks returned were exhaustively searched for re-
levant journal articles or reports, and any found were retained.
2.1.3. Document selection strategy
The abstract of each retained article was read. If it reported new
statistics or methods for generating statistics based on an indicator of
early diagnosis from population-based data sources (inclusion criterion
1, Appendix A in Supplementary data), the article’s full text was read.
The summary, introduction and conclusion of retained reports were
read. Those meeting the above inclusion criterion were identiﬁed.
Relevant portions of the full text of these reports were then read.
Details regarding the early diagnosis indicators and their association
with any measure related to survival (complications, mortality, sur-
vival, life expectancy, or cure (inclusion criterion 2, Appendix A in
Supplementary data)) were extracted.
2.2. Data analysis
2.2.1. Patient cohort
Cancer registrations were obtained from the Oﬃce for National
Statistics (ONS) for adults aged 15–99 years, diagnosed with colorectal
cancer, NSCLC or ovarian cancer in England in 2006–2013 (ICD-10
codes C18-20, C21.8, C33-34 and C56-C57.7 [10]). Follow-up was
complete up to 31 December 2014. Registrations were linked to data-
sets from the National Bowel and Lung Cancer Audits, and to the Routes
to Diagnosis dataset [11] using the patient’s NHS number and postcode.
These datasets were used to complete information on stage at diagnosis
[12].
2.2.2. Data analysis
Thirty-day mortality and one- and ﬁve-year net survival were esti-
mated by agegroup (15–59, 60–79, 80–99 years). Net survival estimates
were obtained using Pohar Perme’s unbiased estimator [13] and the
period approach applied to follow-up data during 2009–2013 for pa-
tients diagnosed during 2006–2013 [14] (details in Appendix B in
Supplementary data).
To avoid unstable sub-group estimates, one-year survival was only
estimated if, in the period 2009–2013, at least 25 patients were diag-
nosed and ﬁve deaths occurred within the ﬁrst year after diagnosis.
Five-year survival was estimated if at least 15 patients were alive at one
year after diagnosis and ﬁve deaths occurred in the second to ﬁfth
years. Missing data was either included in a separate category, or ex-
cluded (complete-case analysis).
3. Results
3.1. Literature search
The PubMed search returned 154 articles (Fig. 1), 19 of which
presented new statistics or methods for generating statistics for an early
diagnosis indicator. The Google search returned ﬁve reports and six
articles also meeting that criterion.
Three early diagnosis indicators were identiﬁed in these 30 docu-
ments: stage at diagnosis (21 documents), emergency admission or
emergency presentation (ﬁve), and interval from ﬁrst symptom to di-
agnosis (eight).
Four documents contained information on survival and two on
mortality.
3.1.1. Indicator 1: Stage at diagnosis
3.1.1.1. Deﬁnition and description. Stage was the sole indicator used in
18 documents (Table 1), and was one of several indicators in a further
three. Typically the TNM classiﬁcation system was used, directly or
using ordinal stage (I–IV). Dukes’ stage for colorectal cancer [16] and
tumour thickness for melanoma [23] were also used. Stage was
frequently dichotomised into ‘early’ (localised, stage I or II, non-
metastatic) vs. ‘late’ (advanced, stage III or IV, metastatic) [16,22].
The CancerData dashboard uses a binary indicator for whether the
patient has a record of stage I/II disease, and presents this as a
percentage of all patients (including those without a recorded stage)
[37]. Other studies imputed stage information [15,19], or analysed
missing stage as a separate group [35]. Average stage at diagnosis
varied by tumour site [38], histological type for ovarian cancer [20],
and by subsite for colorectal cancer [33].
3.1.1.2. Association with patient survival. Early-stage disease was
associated with higher survival (net, relative or unadjusted). Women
diagnosed with breast cancer during 2000–2007 in northeast England
had one-year net survival over 90% at stages I-III, but only 50% at stage
IV [15]. Five-year survival was high for women diagnosed at stage I/II,
substantially lower for stage III and lower still for stage IV. There was a
similar pattern for patients diagnosed in England during 1996–2002
with colorectal cancer: ﬁve-year survival was 93.2% for the patients
diagnosed with Dukes’ A, 47.7% for Dukes’ C, and 6.6% for stage D
[35].
3.1.2. Indicator 2: Emergency admission or presentation
3.1.2.1. Deﬁnition and description. Emergency admission or
presentation was mentioned in ﬁve documents (Table 1). This is
deﬁned as an admission coded as ‘emergency’ and/or ‘accident &
emergency’ [16], or a route to diagnosis via the Accident & Emergency
department or via an emergency referral or transfer [11].
3.1.2.2. Association with short-term mortality and survival. Elliss-Brookes
et al. [11] found an association between emergency presentation and 1-
year relative survival, noting “the substantially lower relative survival
in emergency compared to non-emergency routes indicates that this
distinction is of high clinical signiﬁcance”.
3.1.3. Indicator 3: Interval from ﬁrst symptoms to diagnosis
3.1.3.1. Deﬁnition and description. Time from ﬁrst cancer-relevant
symptom to referral or diagnosis was used in eight documents (Table 1).
The interval start was the time the patient ﬁrst noticed symptoms
[34,39,40] or time of presentation with symptoms to the GP [17,18,42].
The relevance of a symptom to cancer was decided by the GP [42],
specialist clinician review [18], or by reference to external standards
[40].
The end-point was cancer diagnosis or referral to secondary care.
One study deﬁned two intervals: the patient interval (time from
symptom onset to ﬁrst clinical presentation), and the primary care in-
terval (time from ﬁrst clinical presentation to specialist referral) [39].
3.1.3.2. Association with short-term mortality and survival. The
association between the intervals and survival varied by cancer. One
study of childhood acute lymphoblastic leukaemia (ALL) found a
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prolonged interval from presentation to diagnosis was associated with
longer event-free survival, although this was attributed to confounding
from disease biology [18]. Another study found a ‘U-shaped’ curve
between interval and odds of death within ﬁve years for ﬁve common
cancers, with higher odds for patients with the shortest and longest
intervals [42]. The high odds of death amongst patients with short
intervals was attributed to confounding, arising because of GPs
expediting diagnosis for patients with high-risk symptoms.
In one survey of expert judgement for 21 common cancers [43,44]
there was consensus that expedited diagnosis brings mortality reduc-
tions for 11 cancers. They were undecided for seven cancers, and dis-
agreed that expedited diagnosis conferred any mortality beneﬁt for
three.
3.2. Data analysis
We analysed the association between stage at diagnosis and emer-
gency presentation with 30-day mortality and survival for 160,617
colorectal, 170,425 non-small cell lung (NSCLC), and 24,450 ovarian
cancer patients (Table 2). Data was not available to examine the in-
terval from ﬁrst symptoms to diagnosis.
3.2.1. Stage at diagnosis: association with 30-day mortality and net survival
Stage was missing for a large proportion of patients in the linked
datasets we analysed (16.1–36.4% of patients for the three cancers).
Colorectal and NSCLC patients aged 60–79 were most likely to be di-
agnosed at stages I or II (43% and 22% respectively), but there were not
substantial diﬀerences between age groups (Table 2). By contrast,
ovarian cancer patients aged 15–59 were considerably more likely to be
diagnosed at stage I/II than those aged 80–99 (48% vs 22%).
Risk of 30-day mortality was higher at higher stages of disease, for
all cancers and age groups, with the exception of colorectal cancer
where mortality risk plateaued at stages II-III (Table 2). Thirty-day
mortality was considerably higher for stage IV patients than stage III
patients: six-times higher for colorectal cancer and three-times higher
for NSCLC and ovarian cancer patients. NSCLC and ovarian cancer
patients with missing stage had even higher mortality than stage IV
patients (37.2% vs. 22.8% for NSCLC; 16.9% vs.12% for ovarian
cancer) whereas mortality for colorectal cancer patients with missing
stage was between that of patients diagnosed at stages III and IV.
One-year colorectal cancer survival was similar for patients diag-
nosed at stages I-III (9.6% diﬀerence between stages I and III) but
markedly lower for stage IV patients (Table 3, Fig. 2). There was no
such plateau in ﬁve-year survival (32.1% diﬀerence between stages I
and III). For NSCLC and ovarian cancer, incremental diﬀerences in stage
category (I vs II, II vs III, III vs IV) were associated with signiﬁcantly
lower one-year and ﬁve-year survival; no plateau was evident. Patients
missing stage had low survival, typically between the survival of pa-
tients with stage III and stage IV disease (Tables 3 and 4).
3.2.2. Emergency presentation: association with 30-day mortality and net
survival
Twenty-three percent of colorectal, 35.6% of NSCLC, and 30.7% of
ovarian cancer patients were diagnosed following emergency pre-
sentation (Appendix C in Supplementary data). Emergency presentation
risk was greater for older patients diagnosed with NSCLC and ovarian
cancer, whilst for colorectal cancer it was most common for patients
aged 15–59 and 80–99 (Table 2).
Emergency presentation was associated with 1.9–2.9 times higher
30-day mortality (Table 2) and lower one-year net survival (Table 3):
50.7% for colorectal cancer compared with 75.9% survival for all routes
combined; 14.1% compared to 32.6% for NSCLC; and 43.7% compared
to 68.2% for ovarian cancer. Diﬀerences were greater for older patients.
Similar patterns were observed for ﬁve-year survival (Table 4).
A small proportion (1.8–2.4%) of patients could not be assigned a
route to diagnosis. Applying the assumption that these were all non-
emergency presentations resulted in small changes in net survival (ty-
pically< 1% and never> 2%) indicating that these results are not
sensitive to missing data (Appendix D in Supplementary data).
Fig. 1. Search strategy with number of reports and journal articles which reported new early diagnosis statistics or methods for generating these (inclusion criterion
(1)), and number reporting the association between an indicator and a measure related to survival (inclusion criterion (2)).
P. Muller et al. Cancer Epidemiology xxx (xxxx) xxx–xxx
3
Ta
bl
e
1
C
an
ce
rs
in
ve
st
ig
at
ed
,
ea
rl
y
di
ag
no
si
s
in
di
ca
to
rs
an
d
su
rv
iv
al
m
ea
su
re
s
us
ed
in
th
e
do
cu
m
en
ts
re
ad
in
fu
ll.
R
ef
er
en
ce
Ea
rl
y
di
ag
no
si
s
in
di
ca
to
r
Su
rv
iv
al
m
ea
su
re
D
oc
um
en
t
ty
pe
C
an
ce
r(
s)
St
ud
y
po
pu
la
ti
on
A
hr
en
sb
er
g
et
al
.[
17
]
∼
In
te
rv
al
fr
om
ﬁ
rs
t
pr
es
en
ta
ti
on
to
di
ag
no
si
s
–
Jo
ur
na
l
ar
ti
cl
e
C
hi
ld
ho
od
ca
nc
er
s/
be
ni
gn
tu
m
ou
rs
of
th
e
C
en
tr
al
ne
rv
ou
s
sy
st
em
(C
N
S)
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
D
an
is
h
ch
ild
re
n
di
ag
no
se
d
in
20
07
–2
01
0
A
it
ke
n
et
al
.[
23
]
^
Tu
m
ou
r
th
ic
kn
es
s
(o
ne
co
m
po
ne
nt
of
TN
M
st
ag
e)
–
Jo
ur
na
l
ar
ti
cl
e
M
el
an
om
a
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
A
us
tr
al
ia
n
pe
op
le
ag
ed
20
–7
5
di
ag
no
se
d
in
20
00
–2
00
3
C
as
ta
no
n
et
al
.[
24
]
^
St
ag
e†
–
Jo
ur
na
l
ar
ti
cl
e
C
er
vi
x
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
En
gl
is
h
an
d
W
el
sh
w
om
en
ag
ed
30
–6
9
di
ag
no
se
d
in
19
90
–2
01
4
C
ho
rl
ey
et
al
.[
26
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
C
er
vi
x,
br
ea
st
,c
ol
or
ec
ta
l
Su
rv
ey
of
En
gl
is
h
ad
ul
ts
ag
ed
50
–7
0
co
nd
uc
te
d
in
20
15
C
io
ca
n
et
al
.[
25
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
M
el
an
om
a
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
Fr
en
ch
pe
op
le
di
ag
no
se
d
w
it
h
m
el
an
om
a
in
20
04
–2
00
8
D
ur
be
c
et
al
.[
27
]
^
Tu
m
ou
r
th
ic
kn
es
s
(o
ne
co
m
po
ne
nt
of
TN
M
st
ag
e)
–
Jo
ur
na
l
ar
ti
cl
e
M
el
an
om
a
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
Fr
en
ch
pe
op
le
di
ag
no
se
d
in
20
04
El
lis
s-
Br
oo
ke
s
et
al
.[
45
]
¥
Em
er
ge
nc
y
pr
es
en
ta
ti
on
R
el
at
iv
e
su
rv
iv
al
fr
om
di
ag
no
si
s
Jo
ur
na
l
ar
ti
cl
e
15
co
m
m
on
ca
nc
er
s
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
En
gl
is
h
pe
op
le
di
ag
no
se
d
in
20
06
–2
00
8
Es
ke
se
n
et
al
.[
28
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
Li
ve
r
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
N
or
w
eg
ia
n
pe
op
le
di
ag
no
se
d
in
20
00
–2
00
9
Es
s
et
al
.[
29
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
Br
ea
st
R
ep
re
se
nt
at
iv
e
sa
m
pl
e
st
ud
y
of
Sw
is
s
w
om
en
di
ag
no
se
d
in
20
03
–2
00
5
G
re
en
le
e
et
al
.[
30
]
^
St
ag
e
(L
oc
al
vs
di
st
an
t)
–
Jo
ur
na
l
ar
ti
cl
e
La
ry
nx
,
or
al
ca
vi
ty
,m
el
an
om
a,
br
ea
st
,p
ro
st
at
e,
co
rp
us
ut
er
i,
ce
rv
ix
,
bl
ad
de
r,
co
lo
re
ct
um
,
es
op
ha
gu
s,
st
om
ac
h,
ki
dn
ey
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
pe
op
le
in
th
e
U
SA
di
ag
no
se
d
in
19
97
–2
00
0
G
up
ta
et
al
.[
18
]
∼
In
te
rv
al
fr
om
ﬁ
rs
t
pr
es
en
ta
ti
on
to
di
ag
no
si
s
Ev
en
t-
fr
ee
su
rv
iv
al
fr
om
di
ag
no
si
s
Jo
ur
na
l
ar
ti
cl
e
A
cu
te
ly
m
ph
ob
la
st
ic
le
uk
ae
m
ia
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
C
an
ad
ia
n
ch
ild
re
n
di
ag
no
se
d
in
19
95
–2
01
1
H
am
ilt
on
et
al
.[
43
]
∼
In
te
rv
al
fr
om
ﬁ
rs
t
sy
m
pt
om
s
to
di
ag
no
si
s
M
or
ta
lit
y
am
on
gs
t
sy
m
pt
om
at
ic
pa
ti
en
ts
Jo
ur
na
l
ar
ti
cl
e
21
co
m
m
on
ca
nc
er
s
Q
ua
lit
at
iv
e
su
rv
ey
of
22
U
K
an
d
D
an
is
h
ex
pe
rt
s
co
nd
uc
te
d
in
20
14
H
re
in
ss
on
et
al
.[
31
]
^
St
ag
e
(I
-I
V
,
no
n-
m
et
as
ta
ti
c
vs
m
et
as
ta
ti
c)
–
Jo
ur
na
l
ar
ti
cl
e
C
ol
or
ec
ta
l
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
Ir
is
h
pe
op
le
di
ag
no
se
d
20
08
–2
01
1
In
de
pe
nd
en
t
C
an
ce
r
Ta
sk
fo
rc
e
[3
8]
^
¥
∼
St
ag
e,
em
er
ge
nc
y
pr
es
en
ta
ti
on
,i
nt
er
va
lf
ro
m
ﬁ
rs
t
re
co
gn
it
io
n
of
sy
m
pt
om
s
to
di
ag
no
si
s
–
R
ep
or
t
A
ll
ca
nc
er
s
N
on
e,
sp
ec
iﬁ
ca
ti
on
of
an
ea
rl
y
di
ag
no
si
s
st
at
is
ti
c
La
ud
ic
el
la
et
al
.[
19
]
^
St
ag
e
I/
II
vs
II
I/
IV
–
Jo
ur
na
l
ar
ti
cl
e
C
ol
or
ec
ta
l,
pr
os
ta
te
,
lu
ng
,b
re
as
t
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
En
gl
is
h
w
om
en
di
ag
no
se
d
in
20
01
–2
01
0
Li
et
al
.[
15
]
^
St
ag
e
N
et
ca
nc
er
su
rv
iv
al
fr
om
di
ag
no
si
s
Jo
ur
na
l
ar
ti
cl
e
Br
ea
st
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
En
gl
is
h
w
om
en
di
ag
no
se
d
in
20
00
–2
00
7
Lu
ri
e
et
al
.[
32
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
O
va
ri
an
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
w
om
en
in
th
e
U
SA
di
ag
no
se
d
in
19
93
–1
99
7
Lu
ri
e
et
al
.[
20
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
O
va
ri
an
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
w
om
en
di
ag
no
se
d
in
th
e
U
SA
in
19
93
–2
00
8
Ly
ra
tz
op
ou
lo
s
et
al
.[
49
]
∼
In
te
rv
al
fr
om
ﬁ
rs
t
re
co
gn
it
io
n
of
sy
m
pt
om
s
to
re
fe
rr
al
,
br
ok
en
in
to
pa
ti
en
t
an
d
pr
im
ar
y
ca
re
in
te
rv
al
s
–
Jo
ur
na
l
ar
ti
cl
e
28
ad
ul
t
ca
nc
er
s
Po
pu
la
ti
on
-b
as
ed
st
ud
y
of
En
gl
is
h
pa
ti
en
ts
pr
es
en
ti
ng
in
pr
im
ar
y
ca
re
in
20
09
–2
01
0
M
ur
ag
e
et
al
.[
16
]
^
¥
St
ag
e
(D
uk
e'
s
A
B
vs
C
D
),
Em
er
ge
nc
y
ad
m
is
si
on
Jo
ur
na
l
ar
ti
cl
e
C
ol
or
ec
ta
l
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
Sc
ot
ti
sh
pa
ti
en
ts
di
ag
no
se
d
in
19
98
–2
01
1
N
at
io
na
l
C
an
ce
r
In
te
lli
ge
nc
e
N
et
w
or
k
[3
5]
^
St
ag
e
N
et
ca
nc
er
su
rv
iv
al
fr
om
di
ag
no
si
s
R
ep
or
t
C
ol
or
ec
ta
l
Po
pu
la
ti
on
-b
as
ed
st
ud
y
of
ad
ul
ts
di
ag
no
se
d
in
En
gl
an
d
in
19
96
–2
00
2
Pu
bl
ic
H
ea
lt
h
En
gl
an
d
[3
6 ]
¥
Em
er
ge
nc
y
pr
es
en
ta
ti
on
–
R
ep
or
t
A
ll
in
va
si
ve
m
al
ig
na
nc
ie
s
N
on
e,
sp
ec
iﬁ
ca
ti
on
of
an
ea
rl
y
di
ag
no
si
s
st
at
is
ti
c
Pu
bl
ic
H
ea
lt
h
En
gl
an
d
[3
7]
^
St
ag
e
(I
,I
I
vs
II
I,
IV
,m
is
si
ng
)
–
R
ep
or
t
Br
ea
st
,
pr
os
ta
te
,c
ol
or
ec
ta
l,
lu
ng
,b
al
dd
er
,k
id
ne
y,
ov
ar
y,
ut
er
us
,n
on
-H
od
gk
in
ly
m
ph
om
as
,
m
el
an
om
a
N
on
e,
sp
ec
iﬁ
ca
ti
on
of
an
ea
rl
y
di
ag
no
si
s
st
at
is
ti
c
R
ub
in
et
al
.[
41
]
¥
Em
er
ge
nc
y
pr
es
en
ta
ti
on
–
Jo
ur
na
l
ar
ti
cl
e
A
ll
ca
nc
er
s
M
ix
ed
-m
et
ho
ds
(i
nt
er
vi
ew
s
an
d
da
ta
an
al
ys
is
)
st
ud
y
of
th
e
En
gl
is
h
G
P
pr
ac
ti
ce
s
in
th
e
pe
ri
od
20
09
–2
01
3
Sa
la
et
al
.[
21
]
^
St
ag
e
–
Jo
ur
na
l
ar
ti
cl
e
Br
ea
st
Po
pu
la
ti
on
-b
as
ed
an
al
ys
is
of
Sp
an
is
h
w
om
en
ag
ed
50
-6
9
w
ho
at
te
nd
ed
sc
re
en
in
g
in
19
95
–2
01
0
(c
on
tin
ue
d
on
ne
xt
pa
ge
)
P. Muller et al. Cancer Epidemiology xxx (xxxx) xxx–xxx
4
3.2.3. Stage at diagnosis and emergency presentation: joint association with
30-day mortality and net survival
Patients diagnosed following emergency presentation were more
likely to be diagnosed at stages III or IV or have stage missing (Table 2).
Emergency presentation was associated with higher 30-day mortality
and lower one- and ﬁve-year net survival for patients at each stage
(Tables 2–4). Survival diﬀerences between emergency and non-emer-
gency colorectal cancer patients increased after the ﬁrst year of follow
up (Appendix E.1 in Supplementary data). By contrast, survival for
emergency and non-emergency NSCLC patients converged to a ‘ﬂoor’
by the ﬁfth year of follow up (Appendix E.2 in Supplementary data).
Patients diagnosed following emergency presentation with missing
stage had extremely high mortality: 26.4–51.0% died within 30 days
following diagnosis (Table 2).
4. Discussion
Stage at diagnosis, emergency admission or presentation, and in-
terval from ﬁrst symptoms to diagnosis are commonly used indicators
of early diagnosis. However, in the literature only stage and emergency
diagnosis have a straightforward relationship with patient survival.
Our data analysis showed that emergency presentation and stage are
independently associated with higher 30-day mortality and lower sur-
vival from colorectal, NSCLC and ovarian cancer in England. Patients
without a recorded stage in population-based datasets had extremely
high 30-day mortality and lower ﬁve-year survival.
4.1. Association between stage and survival
One-year survival from colorectal and breast cancers plateaued at
stages I-III and was markedly lower at stage IV, whereas NSCLC and
ovarian cancer displayed no such plateau. Five-year survival did not
plateau at any stages for any cancer: each incremental increase in stage
was associated with substantially lower survival. Granular information
on stage at diagnosis, as opposed binary groupings, is therefore useful
for monitoring progress in eﬀorts to raise medium-term survival, al-
though certain binary stage groupings may produce statistics which are
strongly associated with short-term survival.
4.2. Association between emergency presentation and short-term mortality
and survival
We found that emergency presentation was associated with higher
30-day mortality and lower medium-term survival for patients at every
age and stage disease, consistent with other studies [44,45]. This in-
dicator is therefore a proxy for other factors which independently de-
termine survival, and is a valuable complimentary prognostic indicator
to stage. However, more work is needed to understand why it is in-
dependently associated with survival.
4.3. Association between interval from ﬁrst symptoms to diagnosis and
short-term mortality and survival
Shorter intervals from ﬁrst symptoms to diagnosis were not con-
sistently associated with improved survival in the literature we ex-
amined. Other reviews concur. Neal et al. found instances of contra-
diction between studies on a given cancer on whether reducing the
diagnostic, referral, or treatment interval was associated with higher
survival or reduced mortality [46]. Hamilton et al found there was no
consensus between experts that expediting symptomatic diagnosis
conferred a mortality beneﬁt for many common cancers [43].
These inconsistent ﬁndings may be partly explained by confounding
by tumour aggressiveness and stage. The ‘waiting times paradox’ of the
shortest intervals being associated with poor survival [42,47] is also
likely to be partially attributable to confounding by these tumour fac-
tors [48]: Stage and aggressiveness may determine both type of ﬁrstTa
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presenting symptoms (in turn determining interval length) and patient
survival. We found evidence suggesting this in the literature: type of
ﬁrst symptoms was associated with the length of interval for childhood
CNS [17], lung cancer [40], and ovarian cancer [20].
4.4. Monitoring performance using early diagnosis indicators
Monitoring of early-stage diagnosis is England is currently con-
ducted using the percentage of patients diagnosed at stage I or II.
However, we have shown that binary groupings of stage lose informa-
tion which is predictive of medium-term survival. Numerical average
stage (1–4) might provide a simple alternative measure that is more
strongly associated with medium-term survival. Within a modelling
framework ordered logistic regression with 4-category stage could be
used instead of logistic regression with a binary stage indicator.
Emergency presentation is associated with advanced stage, and
higher mortality and lower survival for patients at each stage. Data on
emergency presentation could therefore be combined with stage in-
formation to generate a more informative prognostic index. Patients
newly diagnosed through a given route at a given stage could be as-
signed a score which is the average survival of patients previously di-
agnosed with the same combination of indicators. For example, if a
patient were diagnosed via emergency presentation at stage II disease,
and previous 1-year survival for patients with these attributes was 80%,
then that patient would be assigned a score of 80. The average score of
the patient population could be then be used for monitoring and
comparisons.
Our results don’t support the use of ‘average diagnostic interval
length’ statistics for benchmarking and performance management. This
is because the very shortest intervals are associated with poorer sur-
vival (due to confounding), so short intervals are not necessarily in-
dicative of success in early diagnosis. However, it would be worthwhile
Table 3
One-year net survival (and 95% conﬁdence interval) by age group, route, cancer, and stage at diagnosis, England 2009–2013.
Ages 15–59 Ages 60–79 Ages 80–99
All routes Emergency presentation All routes Emergency presentation All routes Emergency presentation
Colorectal cancer
I 99.3 (98.9, 99.7) 98.3 (96.7, 100.0) 98.8 (98.4, 99.1) 90.5 (87.2, 93.8) 93.7 (92.3, 95.1) 67.6 (61.9, 73.3)
II 97.8 (97.2, 98.3) 95.5 (93.9, 97.0) 95.2 (94.8, 95.6) 86.6 (85.1, 88.2) 87.7 (86.7, 88.8) 72.0 (69.5, 74.5)
III 95.4 (94.8, 96.0) 90.0 (88.0, 91.9) 90.6 (90.1, 91.1) 78.3 (76.7, 80.0) 76.2 (74.9, 77.5) 58.4 (55.7, 61.0)
IV 62.9 (61.7, 64.1) 48.9 (46.6, 51.2) 50.0 (49.3, 50.8) 31.2 (30.0, 32.5) 27.6 (26.6, 28.6) 15.2 (14.0, 16.5)
Missing 86.5 (85.7, 87.2) 75.6 (73.8, 77.5) 79.6 (79.1, 80.1) 52.1 (50.8, 53.4) 52.5 (51.7, 53.3) 30.2 (29.1, 31.3)
Total 85.6 (85.1, 86.0) 73.2 (72.0, 74.3) 80.7 (80.4, 81.0) 55.8 (55.0, 56.5) 59.9 (59.4, 60.4) 35.9 (35.0, 36.7)
Non-small cell lung cancer
I 92.9 (91.8, 94.1) 84.9 (80.1, 89.8) 85.0 (84.3, 85.7) 67.0 (64.6, 69.4) 70.2 (68.6, 71.8) 49.2 (46.2, 52.2)
II 81.4 (79.1, 83.6) 70.7 (63.3, 78.0) 69.0 (67.8, 70.2) 45.9 (42.7, 49.0) 48.0 (45.9, 50.2) 30.5 (27.0, 34.0)
III 54.3 (52.8, 55.8) 34.6 (31.3, 37.9) 43.2 (42.5, 43.8) 23.5 (22.3, 24.8) 26.8 (25.8, 27.9) 14.6 (13.2, 16.0)
IV 24.0 (23.2, 24.9) 15.0 (13.9, 16.1) 16.9 (16.5, 17.2) 7.6 (7.3, 8.0) 10.0 (9.5, 10.5) 5.2 (4.8, 5.7)
Missing 39.4 (37.8, 41.1) 19.1 (17.0, 21.3) 24.4 (23.7, 25.0) 9.4 (8.8, 10.1) 12.3 (11.7, 12.9) 6.8 (6.2, 7.4)
Total 42.4 (41.7, 43.0) 22.1 (21.1, 23.1) 35.2 (34.9, 35.5) 14.7 (14.3, 15.1) 22.0 (21.6, 22.4) 10.7 (10.3, 11.2)
Ovarian cancer
I 98.1 (97.4, 98.7) 96.0 (93.6, 98.4) 97.1 (96.1, 98.1) 90.3 (85.1, 95.5) 93.2 (89.2, 97.3) 64.4 (48.4, 80.4)
II 92.3 (89.7, 94.8) 80.4 (70.1, 90.8) 90.3 (87.6, 93.0) 83.7 (74.2, 93.2) 73.0 (64.3, 81.8) 36.4 (16.9, 56.0)
III 87.7 (86.0, 89.3) 79.7 (75.7, 83.8) 76.3 (74.8, 77.9) 59.7 (56.2, 63.1) 49.3 (45.3, 53.3) 27.2 (21.4, 33.0)
IV 72.2 (69.3, 75.1) 64.9 (59.9, 69.9) 57.3 (55.3, 59.4) 43.6 (40.4, 46.8) 21.4 (18.5, 24.2) 11.2 (8.3, 14.1)
Missing 82.0 (80.4, 83.5) 65.0 (61.3, 68.7) 58.4 (56.9, 59.8) 36.6 (34.2, 38.9) 22.7 (21.0, 24.5) 11.9 (10.1, 13.6)
Total 86.9 (86.1, 87.6) 73.9 (71.8, 76.0) 69.5 (68.7, 70.4) 46.8 (45.1, 48.4) 33.1 (31.7, 34.6) 14.8 (13.2, 16.3)
Fig. 2. Net survival (with 95% conﬁdence intervals (CI)) at one and ﬁve years by cancer, stage, and route to diagnosis, England.2009–2013.
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to monitor whether reductions in average diagnostic intervals in re-
sponse to an intervention in an area are associated with changes in the
stage distribution or survival, to evaluate the eﬀectiveness of the in-
tervention.
Further work is also needed to identify alternative statistics based
on the interval or similar quantities which are useful for surveillance.
Alternative measures could include statistics on ‘missed opportunities’
for prompt symptomatic diagnosis: Lyratzopoulos et al. have described
how these can occur [49], and Renzi et al identiﬁed instances of these
for colorectal cancer [50].
We found that anatomical site of origin was strongly associated with
probability of early diagnosis, regardless of the indicator used. The
distribution of cancers should therefore be accounted for in perfor-
mance comparisons, either through standardisation a modelling ap-
proach, to reduce bias from case-mix diﬀerences.
4.5. Interpreting missing stage information
In the English datasets we examined 16–36% of patients had no
recorded stage. Compared to patients with a recorded stage, these pa-
tients had very high risk of death shortly following diagnosis and lower
medium-term survival.
There are likely to be two diﬀerent reasons why patients do not have
a recorded stage. For most patients missing stage, it may be for ad-
ministrative (non-clinical) reasons. These patients would have a similar
stage distribution and survival to those with recorded stage. For a
minority, it may have not been recorded because the patient was acutely
unwell or had very poor prognosis at the time of ﬁrst presentation.
These patients would have more advanced disease, and many would die
shortly after diagnosis. This hypothesis, that the majority of patients
missing stage have typical stage and survival, and a minority have more
advanced disease and very poor survival, explains the heterogeneity in
30-day mortality and survival we observed. It is also consistent with
results from the study by Barclay et al suggesting that the stage dis-
tribution of these patients is slightly skewed towards later stages [51].
Our ﬁndings suggest that patients missing stage should be included
in surveillance to avoid bias. This could be done using multiple im-
putation for missing data [52], using a ‘missing stage and died shortly
following diagnosis’ percentage, or by applying expected survival sta-
tistics or model-based scores.
4.6. Strengths and limitations
We conducted a comprehensive joint analysis of the association
between stage and emergency presentation with survival using 355,502
patient records, and compared results from this to the published lit-
erature. We also analysed the survival of patients missing a recorded
stage, who comprise a substantial proportion of patients.
We restricted the literature search to documents explicitly men-
tioning ‘early diagnosis’. This approach gave us insight into what people
consider ‘early diagnosis’ to encompass, however, it excluded studies
where explicit mention of ‘early diagnosis’ was absent, so some data on
the association between an indicator and patient survival may have
been omitted.
4.7. Conclusion
In this study we identiﬁed the diﬀerent indicators used to measure
early diagnosis, and examined the association of each of the indicators
with short-term mortality and survival. We recommend several changes
to early diagnosis surveillance in England based on our ﬁndings: that
granular stage information should be used in stage statistics to improve
their prognostic value; that patients without a recorded stage should be
included in surveillance to minimise bias; and that data on patient’s
stage and route to diagnosis could be combined to create a composite
early diagnosis indicator.
Shorter diagnostic intervals can be a result of late-stage disease and
of patients being acutely unwell, and therefore we conclude that the
average length of diagnostic interval is not an informative measure for
performance management. More work is needed to examine the asso-
ciation between reductions in diagnostic interval length and survival
improvements in an area, and to develop informative statistics based on
the diagnostic interval for use in surveillance.
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Table 4
Five-year net survival (and 95% conﬁdence interval) by age group, route, cancer, and stage at diagnosis, England 2009–2013.
Ages 15–59 Ages 60–79 Ages 80–99
All routes Emergency presentation All routes Emergency presentation All routes Emergency presentation
Colorectum
I 94.5 (92.6, 96.4) 93.4 (87.2, 99.5) 97.1 (95.7, 98.4) 74.4 (65.8, 82.9) 91.8 (86.2, 97.4) 58.4 (44.9, 71.9)
II 87.3 (85.6, 89.1) 78.4 (73.7, 83.2) 86.2 (85.0, 87.4) 68.5 (65.3, 71.8) 77.2 (73.7, 80.6) 50.6 (44.1, 57.0)
III 71.3 (69.4, 73.1) 57.5 (52.7, 62.2) 66.9 (65.7, 68.1) 42.3 (39.3, 45.4) 47.9 (44.9, 50.9) 29.7 (24.1, 35.2)
IV 19.7 (18.4, 20.9) 12.9 (11.0, 14.8) 15.3 (14.6, 16.0) 7.2 (6.3, 8.1) 7.3 (6.4, 8.3) 3.8 (2.6, 5.0)
Missing 68.9 (67.9, 69.8) 55.4 (53.3, 57.5) 64.2 (63.6, 64.8) 33.5 (32.3, 34.7) 37.7 (36.7, 38.7) 17.6 (16.4, 18.8)
Overall 63.2 (62.6, 63.9) 47.4 (45.9, 48.8) 62.0 (61.6, 62.5) 33.0 (32.2, 33.8) 42.9 (42.1, 43.8) 20.6 (19.5, 21.6)
NSCLC
I 67.7 (65.0, 70.5) 52.6 (44.4, 60.7) 50.8 (49.4, 52.3) 29.7 (26.2, 33.1) 29.8 (26.8, 32.8) 13.3 (8.4, 18.1)
II 46.3 (42.7, 50.0) 43.1 (33.4, 52.7) 29.9 (28.1, 31.6) 18.5 (15.1, 21.9) 12.9 (10.0, 15.8) 6.0 (1.7, 10.3)
III 13.1 (11.9, 14.3) 7.5 (5.5, 9.6) 8.3 (7.8, 8.8) 3.3 (2.6, 4.0) 3.5 (2.8, 4.3) 1.2 (0.4, 2.0)
IV 3.9 (3.4, 4.3) 2.6 (2.0, 3.3) 1.8 (1.6, 2.0) 0.8 (0.6, 1.0) 1.3 (1.0, 1.7) 1.1 (0.6, 1.5)
Missing 17.9 (16.8, 19.0) 6.8 (5.6, 8.0) 7.9 (7.5, 8.3) 2.2 (1.9, 2.5) 2.5 (2.1, 2.8) 0.8 (0.5, 1.0)
Overall 16.6 (16.0, 17.1) 6.9 (6.2, 7.5) 11.5 (11.3, 11.8) 3.5 (3.2, 3.7) 5.3 (4.9, 5.6) 1.7 (1.4, 2.1)
Ovarian cancer
I 88.3 (86.4, 90.2) 86.8 (82.1, 91.5) 86.5 (83.8, 89.3) 72.9 (63.2, 82.5) 81.6 (70.0, 93.1) 53.4 (26.5, 80.3)
II 74.7 (70.0, 79.4) 55.9 (42.4, 69.3) 63.1 (57.5, 68.7) 49.7 (34.6, 64.9) 37.2 (23.3, 51.1) 15.8 (-0.2, 31.8)
III 41.5 (38.4, 44.5) 31.5 (25.8, 37.2) 24.9 (22.9, 26.9) 14.4 (11.4, 17.4) 11.4 (7.4, 15.5) 3.6 (0.5, 6.6)
IV 26.6 (23.4, 29.8) 18.4 (13.5, 23.3) 13.8 (12.1, 15.5) 8.2 (6.1, 10.2) 3.6 (1.7, 5.4) 0.0 (0.0, 0.1)
Missing 55.2 (53.4, 57.0) 33.5 (30.2, 36.7) 25.1 (23.9, 26.2) 9.5 (8.2, 10.8) 8.1 (6.9, 9.4) 3.3 (2.2, 4.4)
Overall 57.9 (56.7, 59.1) 38.9 (36.5, 41.3) 31.7 (30.8, 32.6) 13.1 (12.0, 14.3) 13.4 (12.0, 14.8) 3.8 (2.7, 4.8)
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